Intarcia Therapeutics is a biopharmaceutical company that develops innovative therapies to help improve the lives of people living with chronic diseases. The company focuses on developing therapies that can provide long-term, sustained delivery of important medications, particularly for diseases such as type 2 diabetes and other metabolic disorders.

Intarcia’s proprietary technology platform, known as the Medici Drug Delivery System, enables the continuous delivery of a range of drugs using a small, implantable device. The system is designed to be long-lasting, requiring infrequent replacement, and has the potential to simplify medication management for patients with chronic diseases.

In addition to developing its own pipeline of therapies, Intarcia also partners with other companies to apply its drug delivery technology to their drugs. The company is committed to improving the treatment options available to patients with chronic diseases and is focused on developing therapies that can improve outcomes and quality of life for these individuals.